Biomed Group
Long/short equity, healthcare, biotech

Heat Biologics: An Undervalued Cancer Vaccine Play That Leaves Considerable Room For Upside

While cancer vaccines have been in clinical trials for more than a decade, to date we have witnessed limited success with only one product (Provenge) approved by the FDA in 2010 to treat prostate cancer in men that have not received chemotherapy. However, the efforts of companies and researchers were not for nothing as lots of data have been collected that would help one day to create a cancer vaccine that would overcome past difficulties. In this article, we will focus on Heat Biologics (NASDAQ:HTBX), a vaccine technology company that is developing various cellular therapeutic vaccines for a range of cancers and infectious diseases. While the company is at an earlier stage of development versus others in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details